Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
| Autor: | Caroline J. Small, Mohammad A. Ghatei, Katie Wynne, Kevin G. Murphy, Michael Patterson, Karim Meeran, Sandra M. Ellis, Gary Frost, Stephen R. Bloom, Adrian Park, Alison M. Wren |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Meal
medicine.medical_specialty business.industry Endocrinology Diabetes and Metabolism Adipose tissue Physical exercise Overweight medicine.disease Obesity Oxyntomodulin chemistry.chemical_compound Endocrinology chemistry Weight loss Internal medicine Internal Medicine Anorectic Medicine medicine.symptom business |
| Zdroj: | Diabetes. 54:2390-2395 |
| ISSN: | 1939-327X 0012-1797 |
| Popis: | This study investigated the effect of subcutaneously administered oxyntomodulin on body weight in healthy overweight and obese volunteers. Participants self-administered saline or oxyntomodulin subcutaneously in a randomized, double-blind, parallel-group protocol. Injections were self-administered for 4 weeks, three times daily, 30 min before each meal. The volunteers were asked to maintain their regular diet and level of physical exercise during the study period. Subjects’ body weight, energy intake, and levels of adipose hormones were assessed at the start and end of the study. Body weight was reduced by 2.3 ± 0.4 kg in the treatment group over the study period compared with 0.5 ± 0.5 kg in the control group (P = 0.0106). On average, the treatment group had an additional 0.45-kg weight loss per week. The treatment group demonstrated a reduction in leptin and an increase in adiponectin. Energy intake by the treatment group was significantly reduced by 170 ± 37 kcal (25 ± 5%) at the initial study meal (P = 0.0007) and by 250 ± 63 kcal (35 ± 9%) at the final study meal (P = 0.0023), with no change in subjective food palatability. Oxyntomodulin treatment resulted in weight loss and a change in the levels of adipose hormones consistent with a loss of adipose tissue. The anorectic effect was maintained over the 4-week period. Oxyntomodulin represents a potential therapy for obesity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|